View attachment 4113752
once again you have no idea ACIp
ADR’s product was a smart inhaler. They don’t need them they can use other ones. At the right price it was a good fit. But todays announcement about the wearable is a TOTALLY different device to a smart inhaler.
It’s exactly the same technology that monitors wheeze use in the wheezo - same algorithm.
Wheezo is self administered for 30sec at point in time -like a Dr uses a stethoscope to hear a patients breathing, wheeze etc - it’s like a heart disease patient taking an on the spot blood pressure reading or an on the spot glucose reading for a diabetic
the overnight monitor takes the reading continuously while the patient sleeps to give the full nights reading to help doctors understand nocturnal asthma - because you can’t wake people up every 30mins or whatever and ask them to breath so they can listen to their breathing, so a wheeze rating can be take ..
diabetics also have a continuous glucose monitor available thru a company called Dexcom (US $37 bn mkt cap (see picture).
it’s the way of the future of monitoring the larger chronic disease's dude..
You need to research a bit more.
hey why don’t you clarify some FACTs and assumptions about why they tried to take over ADR by actually participating in the QandA
It stands for: “ask a question you don’t know the answer for and then, get the answer..
(20min delay)